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The human integrin glycoprotein IIb/IIIa complex plays a central role in haemostasis as an inducible receptor for fibrinogen and other adhesive 
proteins at the platelet plasma membrane. Current evidence indicates that the ligand-binding domain of GPIIb/IIIa is discontinuous and placed 
at the subunit interface. Here we show that a synthetic peptide containing the polypeptide stretch GPIIb 656667, which is hidden within the resting 
platelet GPIIb/IIIa heterodimer but becomes exposed following platelet activation with thrombin, binds to soluble fibrinogen (n = 2.3 f 1.3; 
Kd = 2 f 0.8 x 10-j M). This interaction is Ca’+ mdependent and can be partially inhibited with synthetic fibrinogen y-chain peptide 400411 but 
not with GRGDS. In addition, peptide GPIIb 656-667 inhibits in a dose-dependent manner the aggregation of activated platelets (ICs, = 170 PM). 
Altogether, our results indicate that the GPIIb 656667 region may form part of the inducible fibrinogen binding site and may not overlap with 
the integrin RGD-recognition domain. 
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1. INTRODUCTION 
Human glycoprotein IIb/IIIa, a Ca2’-dependent 
heterodimer, is the major integrin on the platelet plasma 
membrane where it serves as an inducible receptor for 
plasma fibrinogen (Fb) and other adhesive proteins, 
including fibronectin (Fn), vitronectin (Vn) and von 
Willebrand factor (vWF) (reviewed in [l]). Dissection of 
the fibrinogen molecule led to the identification of sev- 
eral putative receptor-recognition sequences within its 
dimeric structure (reviewed in [2]). Notably, small syn- 
thetic peptides containing the amino acid sequence Arg- 
Gly-Asp (RGD), which is present within the primary 
structure of Fb, Fn, Vn, and vWF, inhibited the binding 
of each of these adhesive proteins to GPIIb/IIIa. In 
addition, a dodecapeptide only found at the C-termini 
of the fibrinogen y-chains (400HHLGGAKQAGDV41’) 
also inhibits the binding of each of the adhesive proteins 
to activated GPIIb/IIIa [2]. Although the binding of 
RGD and y-chain peptides is mutually exclusive (re- 
viewed in [3,4]), immunological data [5], studies on re- 
combinant human fibrinogen [6], and examination by 
electron microscopy of the interaction of isolated 
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GPIIb/IIIa with fibrinogen [7], all suggest hat the C- 
terminus of the y-chain contains the essential informa- 
tion for receptor binding. 
On the other hand, human platelet GPIIb/IIIa is the 
most thoroughly studied integrin [3]. However, despite 
the wealth of information regarding structure-function 
relationships of GPIIb/IIIa (integrin 01,&), the precise 
structure of the heterodimer, and consequently the rela- 
tionship between the y-chain- and the RGD-binding 
site(s), remain obscure. In addition, the identification of 
a variety of GPIIb and GPIIIa domains putatively in- 
volved in ligand recognition (reviewed in [3,8]) indicates 
that the integrin’s receptor surface may be made up of 
regions from both subunits which, although distantly 
located within the linear primary structure, are brought 
into juxtaposition by the spatial folding of the polypep- 
tide chains [9]. Here, we have focused on the GPIIb 
656667 polypeptide stretch because this region (a) con- 
tains the epitope for the platelet aggregation inhibitory 
monoclonal antibody M6, whose surface expression on 
GPIIb/IIIa is platelet activation-dependent, and (b) 
shows a high hydropathic complementary to the fibrin- 
ogen ~402411 GPIIb/IIIa recognition sequence [lo]. 
Our results show that synthetic GPIIb 656667 binds to 
soluble human fibrinogen with a dissociation constant 
of 2 A 0.8 x lo-’ M in a Ca2’- and RGD-independent 
manner. In addition, GPIIb 656667 inhibits ADP-in- 
duced platelet activation with an IC,, of around 170 
,uM. Taken together, these data indicate that the GPIIb 
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656-667 domain fulfills the requirements expected for 
an inducible fibrinogen-specific recognition domain. 
2. MATERIALS AND METHODS 
2.1. Peptide synthesis 
Peptides GRGDS, GPIIb65U67 (GAHYMRALSNVE) [21], CGA- 
HYMRALSNVE (Cys-GPIIb656667), and HHLGGAKQAGDV 
(r”““) were synthesized using a semi-automated peptide synthesizer 
(Labortec SP 640) as described [lO,ll]. The molecular masses of the 
peptides were measured by fast atom bombardment mass spectrome- 
try using a MAT 900 instrument (Finnigan MAT, Bremen) equipped 
with a liquid secondary-ion ionization system. Quantification of pep- 
tides was done by amino acid analysis after hydrolysis with 6 N HCI 
for 24 h at 11O’C. 
concentration-dependent ability of synthetic GPIIb 
656667 peptide to inhibit the fibrinogen-mediated ag- 
gregation of human gel-filtered platelets activated with 
ADP Inhibition reached 93% when the final concentra- 
tion of peptide was 1 mM. The calculated I(& from two 
experiments was 173 + 10 ,uM. 
2.2. Selective labeling and purification 
For selective labeling of the N-terminal cysteine residue with eosin- 
5’ iodoacetamide (Molecular Probes, Eugene, Oregon), 100 mg of side 
chain-protected resin-attached peptide Cys-GPIIb656667 were swollen 
in 1 ml dichloromethane for 30 min, washed twice with dimethylfor- 
mamide (DMF), and incubated with 100 ,~ul (DMF), 10 ,~l deionized 
water, 23 ~1 trihutylphosphine, and 5 ~1 triethylamine, for 2 h at room 
temperature with gentle stirring. This treatment selectively releases the 
Stert-butyl group from the N-terminal cysteine. After exhaustive 
washing with DMF, the peptide was incubated with a 1.5 molar excess 
of eosin-5’iodoacetamide in DMFllOO mM phosphate pH 8.0 (80:20, 
v/v) for 4 h at room temperature, in the dark, and under continuous 
stirring. Thereafter, the excess of dye was extracted with DMF (until 
the eluent did not absorb at 530 nm), and the labeled peptide was 
deprotected and released from the polymeric resin by treatment with 
85% (v/v) trifluoroacetic acid and 5% (v/v) thioanisol for 6 h at room 
temperature with gentle stirring. The peptide was precipitated with 
diethylether and purified by reverse-phase HPLC using a Lichrospher 
RP-100 Cl8 column (Merck, Darmstadt) (25 x 0.4 cm, 5 pm particle 
size) eluted at 1 mUmin with a gradient of 0.1% (v/v) trifluoroacetic 
acid in water (A) and acetonitrile (B) as follows: isocratically (15% B) 
for 5 min, followed by 1560% B for 90 min. The eluate was monitored 
at both 220 and 490 nm. 
2.3. Platelet aggregation i hibition experiments 
Platelet aggregation inhibition experiments were performed as de- 
scribed [12]. Briefly, 400 ,~l platelet suspension ahquots (3 x 10’ plate- 
lets/ml in Tyrode’s buffer) were activated at 37°C with 10 ~1 ADP (60 
PM, final concentration) and mixed with 40 ~1 of fibrinogen solutions 
(0.6 mg/ml) which had been preincubated at 37’C with the GPIIb65”“67 
peptide (final concentration ranging from 30 ,uM to 10 mM). 
Solid-phase (ELISA) analysis using eosin-labeled 
GPIIb peptide showed that it does not interact with 
isolated GPIIb/IIIa but binds in a concentration-de- 
pendent manner to immobilized human fibrinogen (not 
shown). The possibility that the eosin moiety might play 
a role in the GPIIb peptide-fibrinogen interaction was 
ruled out because the unlabeled peptide competes quan- 
titatively with the labeled one for binding to immobi- 
lized fibrinogen. We then studied the interaction of 
eosin-labeled GPIIb 656667 peptide with human fi- 
brinogen in solution (TBS buffer, pH 7.4, 20°C) by 
equilibrium sedimentation. Fig. 2 shows the equilibrium 
sedimentation distribution of fibrinogen (6 PM) in the 
presence of 20 PM peptide recorded at 300 nm (A), a 
wavelength where the peptide but not eosin absorb, and 
at 530 nm (Fig. 2B CO), where only eosin absorbs. This 
indicates that the synthetic peptide cosedimentes with 
fibrinogen. The interaction was apparently specific for 
fibrinogen, since the synthetic peptide did not bind to 
other proteins, like catalase (Fig. 2B, a-+), and fol- 
lowed the equation [L,] = [L] + B[P] (Fig. 3), where [L,] 
is the total peptide concentration, [L] is the concen- 
tration of free peptide (Y-axis intercept), and [P] is the 
concentration of fibrinogen. Assuming a single class of 
equivalent and independent binding sites, B (the slope) 
can be defined as n K [L]/( 1 + K[L]) [ 151, where K is the 
association constant, and n the number of binding sites. 
Chi-square was minimized using a non-linear least 
square procedure based on the modified Nelder-Mead 
simplex algorithm [16]. Representation of B versus 
log[L] (Fig. 4) allowed us to determine the following 
parameters: n = 2.3 f 1.3 and K = 2 + 0.8 x 10T5 M. In- 
terestingly, the GPIIb 656667 synthetic peptide-fibrin- 
2.4. Equilibrium sedimentation - 
The interaction of soluble human fibrinogen (6 PM in 10 mM 
Tris-HCl, 150 mM NaCl, pH 7.4, containing either 1 mM CaCl, or 
1 mM EGTA) with different amounts of eosin-labeled peptide Cys- 
GPIIb65”667 (10m6 to 10e3 M) was analyzed by short column sedimen- 
tation equilibrium experiments, performed essentially as described 
[13,14], using an XLA Optima analytical ultracentrifuge (Beckman 
Instruments Inc., Palo Alto) run at 10,000 rpm and 20°C. The equihb- 
rium distributions of human fibrinogen and eosin-peptide were deter- 
mined by radial scanning at 300 nm and 530 nm, respectively. Similar 
experiments were performed in the presence of 1 mM (final concentra- 
tion) of either peptide GRGDS or GAHYMRALSNVE. 
3. RESULTS AND DISCUSSION 
If GPIIb 656667 constitutes an element of the fibrin- 
ogen-recognition domain in GPIIb/IIIa, then it may 
interact directly with fibrinogen inhibiting thereby 
platelet aggregation. Fig. 1 shows a typical curve of the 
s 
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Fig. 1. Dose-dependent inhibition of the fibrinogen-mediated aggrega- 
tion of washed platelets activated with ADP by synthetic peptide 
GAHYMRALSNVE (GPIIb 65-7). IC,, is the final concentration of 
peptide causing 50% of maximal inhibition. 
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Fig. 2. (A) Equilibrium sedimentation profile of human fibrinogen (6 
PM in TBS pH 7.4) at 10,000 rpm, 2O”C, detected at 300 nm; r, radius. 
(B) Equilibrium sedimentation profile (as in A) at 530 nm of eosin- 
labeled peptide Cys-GPfIb 656667 (20 PM) in the presence of 5 pM 
catalase (+-_*), 6 pM fibrinogen (CXJ), and 6 FM fibrinogen + I mM 
g-chain 4OD-411 peptide (x-x). Each curve is the average of 24 exper- 
iments. 
ogen binding could be partially (around 30%) reverted 
with 1 mM fibrinogen y-chain 400-411 peptide (Fig. 
2B, x-x), but not with 1 mM GRGDS peptide (curve not 
shown), and was not affected by either 1 mM CaCl, or 
1 mM EGTA. 
The low inhibition of GPIIb 656667 (20 PM) bind- 
ing to soluble fibrinogen (6 FM) exert by 1 mM syn- 
thetic y-chain 400411 peptide (Fig. 2B) suggests that 
only a small population of the isolated synthetic fibrin- 
ogen peptide adopts an active conformation in solution, 
or that the binding of the GPIIb peptide to fibrinogen 
stabilizes a preferred conformer. The first possibly 
would be in accordance with a recent two-dimensional 
‘H-NMR study of the conformation of the 392411 
segment of human fibrinogen y-chain in aqueous solu- 
tion [17]. 
Both its ability for binding fibrinogen in solution and 
its selectivity for the y-chain make GPIIb 656667 
unique among the peptides derived from GPIIb [7,18] 
or GPIIIa [19,20] reported to bind to fibrinogen. Our 
data favor the hypothesis that y-chain- and RGD-pep- 
tides bind to different sites in GPIIb/IIIa. On the other 
hand, the fact that (a) the peptide-fibrinogen i teraction 
is Ca”-independent, whereas the binding of fibrinogen 
to activated platelets requires Ca2’ [21,22], and (b) the 
affinity of the peptide-fibrinogen binding is two orders 
of magnitude lower that that of fibrinogen for its acti- 
vated receptor (.& -0.1 x 10m6 M) [23], indicate that 
GPIIb 656-667 mimics to a certain extent but does not 
completely represent he fibrinogen y chain recognition 
site of GPIIb~IIa. This is not surprising, however, as 
the whole fibrinogen distal (D) domain (90 kDa, which 
includes mainly the C-terminal domains of the /? and y 
chains) is 70-fold more active than the synthetic y400- 
411 peptide in inhibiting ADP-induced platelet aggrega- 
tion [24]. This clearly indicates that a much larger sur- 
face than that provided by the C-terminal y-chain pep- 
tide must be involved in receptor-ligand interaction. In 
addition, receptor-induced binding sites (RIBS) within 
the fibrinogen structure, which are elicited upon interac- 
tion with placelet membrane GPIIblIIIa [25,26], might 
be involved in further inte~ctions confering high-Ann- 
ity to the fibrinog~-GPIIb~IIa association. 
As several integrin receptors which share the same 
b-subunit (homologous to GPIIIa) recognize different 
ligands [27,28], the distinct a-subunits (homologous to 
GPIIb) must impart ligand specificity. Thus, it is note- 
worthy that the GPIIb 656667 region has been poorly 
conserved within the primary structure of integrin 01- 
chains. In particular, this GPIIb sequence (GA- 
HYMRALSNVE) corresponds to QADFIGWRNNE 
of the vitronectin receptor a-subunit (a,) [29]. The vi- 
tronectin receptor (VnR) shares with GPIIblIIIa the 
~-subunit and the overall amino acid sequence identity 
between a, and GPIIb is 60%;. Interestingly, although 
both VnR and GPIIb/IIIa are promiscuous receptors 
which bind fibrinogen, the former only recognizes an 
0.60 0.90 1.20 
[Fibrinogen1 x I O-‘H 
Fig. 3. Representation of the linear relationship between the concen- 
trations of eosin-labeled peptide Cys-GPIIb 656667 and fibrinogen 
obtained by analysis of experiments done as in Fig. 1 when 
[L] = 1.57 x 10e5 M, and B = 1.00 mol GPIIb peptide/mol fibrinogen 
(DO); and [L] = 2.07 x 10m5 M, and B = 0.68 mol GPIIb peptide/mol 
fibrinogen (e*). 
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Fig. 4. Graphical relationship between the logarithm of the concentra- 
tion of free peptide eosin-Cys-GPIIb 656667 (log [L]) and B (average 
of 3 different experiments). At saturation, B tends to n = 2.3 * 1.3. 
epitope containing the RGD sequence at position 572- 
574 of the Fb Aa chain, whereas GPIIb/IIIa binds pref- 
erentially to the Fb D-domain including the y-chain 
400-411 site [6,7,30,31]. These observations together 
with our present results suggest hat the GPIIb 656667 
amino acid sequence may contribute to the binding 
specificity of GPIIb/IIIa. On the other hand, since the 
interaction of the GPIIb peptides 296306 and 300-3 12, 
and the GPIIIa sequences 211-222 and 217-231) with 
fibrinogen can be inhibited by both RGD and gamma- 
chain peptides [7,18-201, it is tempting to speculate that 
these receptor regions, which are highly conserved be- 
tween different integrins, may be important for recogni- 
tion of RGD-containing ligands, i.e. fibronectin, vitro- 
nectin, von Willebrand factor, and fibrinogen antago- 
nists like disintegrins [32,33], ornatins [34], mambin 
[35], and decorsin [36]. 
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